Crohn's disease trials in Czechia

In Czechia 25 Also abroad 422

25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
Where
Brno-Stred, Brno-Zidenice, Hradec Králové, Prague, Slaný
Age
18 years and over
People
567 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Brno-Stred, Brno-Zidenice, Hradec Králové, Prague, Slaný
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 3Taking people
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Where
Brno-Zidenice, Hradec Králové
Age
18 years and over
People
1,380 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06651281 · EU 2024-513533-20-00
Phase 2Taking people
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Where
Brno-Sever, Brno-Zidenice, Prague 4, Prague 5
Age
18 years to 85 years
People
385 worldwide
Run by
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00
Phase 3Taking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Brno, Hradec Králové, Ostrava, Prague, Ústí nad Labem
Age
18 years to 70 years
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Brno, Brno-Zidenice, Kladno, Olomouc, Pardubice, Prague, Prague 4
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Brno, Hradec Kralova, Hradec Králové, Ostrava - Poruba, Prague
Age
18 years and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Hradec Králové, Kladno, Ostrava, Prague
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Brno, Brno-Sever, Brno-Zidenice, České Budějovice, Hradec Králové, Olomouc, Ostrava, Pardubice, Prague, Prague 5, Slezska Ostrava, Ústí nad Labem
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 2Taking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Brno-Zidenice, České Budějovice, Hradec Králové, Olomouc, Slaný
Age
18 years to 75 years
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Hradec Králové, Ostrava, Prague, Usti Nad Labem
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Brno, Hradec Králové, Prague
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Hradec Králové, Prague
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Novy Hradec Kralove, Prague 2, Prague 5
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
No phaseTaking people
Impact of Ultra-Processed Food Reduction on Remission Duration in Pediatric Crohn's Disease
Where
Prague
Age
10 years to 18 years
People
124
Run by
University Hospital, Motol
See details and how to joinNCT07884045
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Brno-Sever, České Budějovice, Hradec Králové, Novy Hradec Kralove
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 2Taking people
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
Where
Brno, Brno-Sever, Brno-Zidenice, Prague
Age
18 years and over
People
160 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Brno-Sever, Hradec Králové, Prague
Age
18 years to 75 years
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00
Phase 3Taking people
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
Where
Brno, Brno-Zidenice, Hradec Králové, Ostrava, Prague
Age
18 years and over
People
302 worldwide
Run by
Janssen Cilag International
See details and how to join2025-521590-13-00 · EU 2025-521590-13-00
Phase 3Taking people
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Where
České Budějovice, Hradec Králové, Prague
Age
18 years to 65 years
People
396 worldwide
Run by
Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00
Phase 2Taking people
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Where
Brno, Brno-Sever, Brno-Zidenice, České Budějovice, Hradec Králové, Ostrava, Pardubice, Prague, Prague 5, Slezska Ostrava, Usti Nad Labem
Age
18 years to 75 years
People
192 worldwide
Run by
Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00
Phase 3Taking people
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Prague
Age
2 years to 17 years
People
240 worldwide
Run by
Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00
Phase 3Taking people
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Where
Ostrava, Prague
Age
2 years to 17 years
People
120 worldwide
Run by
Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00
Phase 2Taking people
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Where
Brno-Sever, Brno-Zidenice, Hradec Králové, Olomouc, Prague, Slaný
Age
18 years to 75 years
People
212 worldwide
Run by
Abivax S.A.
See details and how to joinNCT06456593 · EU 2023-508234-34-00
Phase 4Taking people
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Where
Brno
Age
18 years to 80 years
People
304 worldwide
Run by
Alimentiv Inc.
See details and how to joinNCT06257706 · EU 2023-509096-16-00